SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...